

MPH Group Data Overview

(Accounting under IFRS):

	01.01. - 30.06.2012		Effective date 30.06.2012	
	Sales in EUR	Net income in EUR	Balance sheet total in EUR	Equity in EUR
MPH Group	99,297,945.28	9,735,040.97	115,631,315.14	68,484,905.12
thereof Pharma segment	87,034,523.50	4,465,470.68		
thereof Healthcare segment	12,263,421.78	5,269,570.29		

	01.01. - 30.06.2011		Effective date 30.06.2011	
	Sales in EUR	Net income in EUR	Balance sheet total in EUR	Equity in EUR
MPH Group	70,271,562.49	5,032,676.70	67,799,305.72	45,678,238.81

Table of Contents

▶ Letter to the Shareholders	2
▶ Group Interim Management Report	3
1. Economic environment	4
General global economy in the first half-year 2012	4
General economy Germany	5
The German pharmaceuticals market	6
2. Business model	7
3. Economic situation	8
Assets, financial position and results	8
4. Outlook	9
▶ Group interim financial statements	11
Group balance sheet - Assets	12
Group balance sheet - Liabilities	13
Group profit and loss summary account	14
Group cash flow statement	15
Group equity change account	16
Group assets development	17
▶ Additional information	19
Information about the members of the company bodies	20
Number of employees	20
The share	21
Glossary	22
Imprint	23



Dear Shareholders, Ladies and Gentlemen

In the first half-year of 2012, the MPH Group extended its business activities by another segment, Healthcare.

The **Pharma** segment consists of the portfolio business of HAEMATO PHARM AG. Here, we continue to see strong growth with patent-free and patent-protected agents in the therapeutic areas oncology, HIV, rheumatism, neurology and cardiovascular diseases. However, the margin suffers from the high legal „compulsory manufacturer discount“ in Germany, which is applicable to c. 90 % of sales (patent-protected medicines) and will remain valid at its current level until the year 2013.

The new **Healthcare** segment comprises the activities bundled in Healthcare Services GmbH. In this segment, the veterinary portfolio business of HAEMATO Vet GmbH and the new business of Healthcare Solutions GmbH (consulting services for pharmacies) and of Nutri Care GmbH (consulting services for nutritional subjects) are organized. In addition, Simgen GmbH (generics and foreign business) and Pharmigon GmbH (production of patient-individual medications) from the investment in Windsor AG are also included here. Within Windsor AG, the sector Health Real Estate is in the project planning phase.

The activities in the **Healthcare** sector are not subject to the German compulsory manufacturer discount and often yield high margins.

With **sales** of 99.29 m Euros, a growth of +41% has been achieved against the preceding year (70.27 m Euros).

The **period's net profit** reached 9.74 m Euros and thus a profit margin of 9.8%.

We are striving for further **growth** in both areas, **Pharma** and **Healthcare**.

Medicines, production and consulting services for therapies of chronic diseases (oncology, HIV, rheumatism and neurology) are our focus areas.

We thank our employees and colleagues for their commitment in the first half year 2012. Their performance makes the permanent further development of the MPH Group possible. Our thanks also go to the supervisory board. In the first half-year of 2012, we have again experienced a constructive cooperation.

We are confident about the further development in the second half of the year.

For the **whole year 2012**, we are aiming at sales of almost 200 m Euros and a renewed increase of profits.

Patrick Brenske
Management Board

Dr. Christian Pahl
Management Board

Group Interim Management Report

▶ 1. Economic environment	4
General global economy in the first half-year 2012	4
General economy Germany	5
The German pharmaceuticals market	6
▶ 2. Business model	7
▶ 3. Economic situation	8
Assets, financial position and results	8
▶ 4. Outlook	9

Group Interim Management Report

1. Economic environment

General global economy in the first half-year 2012


At the end of the first half of 2012, the global business cycle is characterized by a rather timid economic expansion. The renewed intensification of the debt crisis in the Euro zone and the associated loss of confidence¹ again darken the perspectives, which had become brighter towards the end of 2011 and in the first months of this year.²

According to the Institut für Weltwirtschaft (IfW), the stronger increase in world production in the first months of this year is caused by a quicker expansion in the emerging countries and a pick-up in production in the advanced economies. In the first quarter of 2012, the global gross domestic product, after an increase of 2.3 % in the fourth quarter of 2011, grew faster again, with an ongoing annual rate of 3.1 %.³

Recently however, the indicators for global production have again become less favorable. The dynamics in the emerging countries have also slowed down noticeably. This can be explained by the weak economy in the advanced economies. The Euro zone is even in recession.⁴

So the IfW expects the global economy to slow down again in the second half-year of 2012. The economic recovery lacks sufficient fundamental dynamics to cope with the disturbances of the financial markets and the increase in raw material prices. However, the IfW assumes that the tensions on the financial markets resulting from the public debt crises in the Euro zone will gradually diminish. A certain relief is also provided here by the noticeable decrease in oil prices. Under this condition, the speed of the global economic expansion should increase again later this year.⁵

ifo World Economic Climate



Source: Ifo World Economic Survey (WES) III/2012

1 cf. Bundesministerium für Wirtschaft und Technologie (BMWi): Schlaglichter der Wirtschaftspolitik. Monthly Report July 2012, p. 25.
 2 cf. Ifw: Weltkonjunktur in unruhigen Fahrwasser. Media communication from 14.06.2012.
 3 cf. id.
 4 cf. id.
 5 cf. id.

General economy Germany

In the first three months of this year, the phase of weakness of the last quarter of last year was overcome with a surprisingly strong spurt of growth. During the second quarter, however, the risks for an economic recovery reappeared again on the scene. In particular, the preoccupations about the economic development in the Euro zone, but also in the USA and China, became more and more significant. In addition, the problems in the banking sectors of some European peripheral states worsened, and the further development of Greece was uncertain. These aspects led to increased nervousness on the financial and stock markets.⁶

These effects burden the business climate and due to the increased hesitation to invest, they weaken the domestic economic growth factors. Nonetheless, the IfW forecasts a strong increase in production. In particular, the extremely low interest rate in Germany produces significant impulses. As far as the situation in the Euro zone does not escalate, these should become increasingly dominant in the second half of the year.⁷

Despite different recent signals, the labor market in Germany continued to evolve in a positive manner. In May, the number of registered unemployed

decreased, a bit less than usual for the season, to 2.855 m. In total, the demand for labor is still on a high level, with only small dips of individual indicators. Due to continued employment with concomitant wage increases, the purchasing power of the consumers is being strengthened further.⁸ Thus, the labor market remains a crucial support for domestic demand.⁹

So despite the difficult international context, the German economy proves stable also in the second quarter of 2012. However, its fundamental dynamics has slowed down. The business climate indicators reflect the increased risks from the international environment, but the ongoing upswing of employment and the positive development of income continue to be an important basis for a robust domestic economy. The latter is, however, still subject to significant external risks.¹⁰

6 cf. Bundesministerium für Wirtschaft und Technologie (BMWi): Schlaglichter der Wirtschaftspolitik. Monthly Report July 2012, p. 5.

7 cf. IfW: Europäische Schuldenkrise bremst den Aufschwung in Deutschland erneut. Media communication from 14. 06.2012.

9 cf. Bundesministerium für Wirtschaft und Technologie (BMWi): Schlaglichter der Wirtschaftspolitik. Monthly Report July 2012, p. 5f.

10 cf. id., S. 5.

The German pharmaceuticals market

Through population growth and increasing per capita spending, the pharmaceutical / healthcare business shows a stronger development than other sectors. The global market is growing by c. 6 % per year. Due to demographic aging, technical progress and increasing purchasing power, healthcare spending in most countries increases faster than the GDP. Until 2013, a growth of the global healthcare market from 5.7 trillion US\$ in 2008 to c. 20 trillion US\$ is expected if this trend continues.¹¹

According to a survey by Bertelsmann Stiftung, health is the most important factor for quality of life for 80 % of the German population.¹² In Germany, the healthcare sector contributes more than 10 % to annual gross value added. Until 2030, according to the Federal Ministry of Economy and Technology, the gross value added is supposed to increase in Germany to more than double the level of 2005.¹³

In May 2012, the German pharmaceuticals market, for the first time since 10 months, showed a sales decrease of 2.9 %. This decrease resulted from statistical effects, for the month of May had two working days less than the respective month of the preceding year.¹⁴ But in the first half-year, sales in the total pharmaceuticals market increased by 2.7 % to 16.1 bn Euros.¹⁵

In the total pharmacies' market, sales in the first half of the year 2012 moderately rose by 2.8 % and amounted to about 12.7 bn Euros at the end of June, minus compulsory manufacturer discounts and the additional discount due to the price moratorium. It was in particular generics (+7 %) and patent-protected preparations (+14 %) that increased. On the contrary, old original drugs lost -16 %.¹⁶

In half of the ten leading drug groups (according to sales) in the pharmacies' market, sales decrease in the first half of the year. On the contrary, drugs for the treatment of chronic diseases, like cardiovascular drugs, showed an increase.¹⁷

In the first six months of 2012 alone, the increased compulsory manufacturer discount, pharmacists' discounts and the wholesale discount led to a savings volume for the statutory health insurance of 1.9 bn. Euro. The mere discounts of the pharmaceutical industry for the statutory and private health insurance amount to 1.4 bn Euros at the end of June of this year.¹⁸

A current analysis of the Robert-Koch-Institut shows that the demographic aging causes an increase of chronic diseases and multimorbidity. In the early adult age, only one fifth of the population has a chronic disease. From the age of 65 on, however, more than half of the people suffer from a chronic disease. In Germany, almost one fifth of the population is 65 years old or older. The high number of cases of age-induced chronic diseases causes high costs.¹⁹

With the therapeutic areas oncology, HIV, rheumatism, neurology and cardiovascular diseases, the MPH Group focuses on therapies for chronic diseases, which will continue to increase in the coming years.

So MPH Group makes a contribution to keeping health affordable.

11 cf. Dr. Kartte, Joachim; Dr. Neumann, Karsten: Weltweite Gesundheitswirtschaft – Chancen für Deutschland. Studie im Auftrag des Bundesministeriums für Wirtschaft und Technologie. Roland Berger Strategy Consultants, 2011, S. 2.

12 cf. Statista/Bertelsmann Stiftung: Umfrage zu wichtigen Faktoren für die Lebensqualität. Was ist Ihnen für Ihre Lebensqualität wichtig?

13 cf. BMWI: Innovationsimpulse der Gesundheitswirtschaft – Auswirkungen auf Krankheitskosten, Wettbewerbsfähigkeit und Beschäftigung. Ergebnisse des gleichnamigen Forschungsprojektes im Auftrag des Bundesministeriums für Wirtschaft und Technologie, p. 4, 21.

14 cf. IMS Health: IMS Market Report. Development of the German pharmaceuticals market in May 2012, p. 8.

15 cf. IMS Health: IMS Market Report. Development of the German pharmaceuticals market in June 2012, p. 8.

16 cf. id., p. 22.

17 cf. id., p. 3.

18 cf. id., p. 4.

19 cf. Robert Koch Institut: GBE Kompakt 2/2012, 3rd year. Zahlen und Trends der Gesundheitsberichterstattung des Bundes. Demografische Alterung und Folgen für das Gesundheitswesen, p.1-6.

2. Business model

MPH Mittelständische Pharma Holding AG comprises the segments Pharma and Healthcare.

The **Pharma** segment consists of the portfolio business of HAEMATO PHARM AG. HAEMATO PHARM AG focuses on the therapeutic areas oncology, HIV, rheumatism, neurology and cardiovascular diseases. With the growth segments Generics as well as with EU import medicines, we offer high-quality and innovative preparations allowing for an affordable medication therapy without any quality cutbacks.

Here, we still see strong growth. However, the margin suffers from the high legal „compulsory manufacturer discount“ in Germany, which is applicable to patent-protected drugs and remains valid on its current level until 2013.

The new segment **Healthcare** comprises the activities bundled in the Healthcare Services GmbH. In this segment, the veterinary portfolio business of HAEMATO Vet GmbH and the new business of Healthcare Solutions GmbH (consulting services for pharmacies) and Nutri Care GmbH (consulting services for nutrition subjects) are organized. In addition, Simgen GmbH (generics and foreign business) and Pharmigon GmbH (production of patient-individual medications) from the investment in Windsor AG are included here. The area of healthcare real estate is in the project planning phase within the segment of Windsor AG.

The Healthcare activities are not subject to the German compulsory manufacturer discount and yield high margins.

Through this double competence and the strategic positioning, the group is able to flexibly react to changes in the pharmaceuticals market that might potentially emerge, e.g. through legal measures of regulation.

MPH understands itself as a partner in the cost-conscious supply of medicines and makes a precious contribution to keeping health affordable!

3. Economic situation

Assets, financial position and results

In the first half-year of 2012, the MPH Group created the new segment Healthcare and achieved sustained growth of sales and earnings in the therapeutic areas oncology, HIV, rheumatism, neurology and cardiovascular diseases.

Sales revenues of the MPH Group rose by +41% to 99.29 m Euros against the preceding year. The net profit was 9.74 m Euros.

On June 30, 2012, the equity reached 68.48 m Euros. The equity ratio was 59.23%.

4. Outlook

Due to the current deterioration of the indicators for global production, the IfW expects a declining global economy also in the second half-year. However, according to the IfW, the tensions on the financial markets should gradually diminish.²⁰

The IfW expects a moderate economic expansion of the advanced economies. Although the monetary policy is still expansionary, the private sector in many countries is still trying to reduce its debt. Besides, contractive influences come from financial policy. So a slowdown of the increase in global production by 3.4 % is expected for 2012. However, in 2013, the global economy is supposed to expand by 3.8 % again.²¹

For the Euro zone, the IfW expects a decrease of GDP by 0.4 % in 2012 and an increase by 0.9 % for 2013. At the same time, the situation of the labor market should deteriorate further.²² The heterogeneous economic development of the Euro countries will remain. Some member countries will partly enter into a marked recession and should only recover slowly and with a more significant delay. Other countries, like Germany, will probably see positive growth rates.²³

For 2012, the IfW expects for Germany an increase of GDP by 0.9 % and of 1.7 % for 2013.²⁴

Contrarily to the external risks for the domestic economy, the IfW forecasts a strong production increase for Germany because significant impulses come from the extremely low interest rates. In the second half of the year, these positive impulses should become increasingly dominant if the situation in the Euro zone does not escalate.²⁵

For the pharmaceutical market, experts expect, together with a continuing demographic aging and increase in purchasing power, a growth of the global health care market of 5.7 trillion US\$ in 2008 to around 20 trillion US\$ until 2013.²⁶ This trend can also be discerned in Germany. In particular, the increase of chronic diseases and multimorbidity will produce further growth of the healthcare market in the coming years.²⁷

For the whole year 2012, the MPH Group aims at a turnover of nearly 200 m Euros and a renewed increase of profits.

20 cf. Ifw: Weltkonjunktur in unruhigem Fahrwasser. Media communication from 14.06.2012.

21 cf. id.

22 cf. id.

23 cf. Bundesministerium für Wirtschaft und Technologie (BMWi): Schlaglichter der Wirtschaftspolitik. Monthly Report July 2012, p. 25.

24 cf. IfW: Europäische Schuldenkrise bremst den Aufschwung in Deutschland erneut. Media communication from 14. 06.2012.

25 cf. IfW: Europäische Schuldenkrise bremst den Aufschwung in Deutschland erneut. Media communication from 14. 06.2012.

26 cf. Dr. Kartte, Joachim; Dr. Neumann, Karsten: Weltweite Gesundheitswirtschaft – Chancen für Deutschland. Studie im Auftrag des Bundesministeriums für Wirtschaft und Technologie. Roland Berger Strategy Consultants, 2011, p. 2.

27 cf. Robert Koch Institut: GBE Kompakt 2/2012 3. Jahrgang. Zahlen und Trends der Gesundheitsberichterstattung des Bundes. Demografische Alterung und Folgen für das Gesundheitswesen, p.1-6.

Group interim financial statements

Group balance sheet - Assets.....	12
Group balance sheet - Liabilities.....	13
Group profit and loss summary account.....	14
Group cash flow statement.....	15
Group equity change account.....	16
Group assets development.....	17

Group balance sheet - Assets

as at 30 June*

	◀ 2012 EUR	◀ 2011 EUR
Cash	8,998,460.08	939,855.12
Trade receivable	9,697,590.57	9,226,888.26
Inventory	36,833,495.53	17,272,247.32
Other financial short-term assets	8,753,174.55	
Other short-term assets	988,520.82	1,427,153.03
Short-term assets	65,271,241.55	28,866,143.73
› Intangible assets	5,275,403.16	1,255,042.17
› Company value	40,168,339.00	37,321,621.72
› Tangible assets	1,236,921.77	268,643.30
› Prepayments	311,716.58	1.00
› Shares in affiliated companies	2,450,000.00	
› Financial assets	240,452.90	
› Other long-term assets	109,661.80	87,574.68
› Deferred tax	567,578.38	279.12
Long-term assets	50,360,073.59	38,933,161.99
▶ TOTAL ASSETS	115,631,315.14	67,799,305.72

* Accounting under IFRS

Group balance sheet - Liabilities

as at 30 June*

	◀ 2012 EUR	◀ 2011 EUR
Accruals	5,394,118.03	1,185,616.04
Bank loan	20,080,781.25	6,604,734.01
Trade payables	6,525,228.12	5,494,383.70
Other financial short-term liabilities	3,442,858.19	
Other short-term liabilities	1,546,191.07	5,332,045.84
Short-term liabilities	36,989,176.66	18,616,779.59
Accruals	232,422.10	
Bond loan	5,239,800.00	
Bank loan	3,500,000.00	3,500,000.00
Deferred tax	1,185,011.26	4,287.32
Long-term liabilities	10,157,233.36	3,504,287.32
Share capital	41,167,155.00	38,050,000.00
Acquired own shares	-4,316,344.00	
	36,850,811.00	38,050,000.00
Capital reserve	4,332,845.00	
Capital reserve for own shares	-6,151,863.84	
Other revenue reserves	-3,354.94	
Retained earnings	18,206,274.12	7,628,238.81
Equity attributable to equity holders of MPH	53,234,711.34	
Non-controlling shareholders	15,250,193.78	
Equity	68,484,905.12	45,678,238.81
▶ TOTAL LIABILITIES	115,631,315.14	67,799,305.72

* Accounting under IFRS

Group profit and loss summary account

for the period from 1 January to 30 June*

	◀ 2012 EUR	◀ 2011 EUR
Sales	99,297,945.28	70,271,562.49
Other operating income	171,710.61	449,605.98
Cost of materials	-83,973,239.48	-60,559,479.97
Labour costs	-1,533,044.55	-1,019,717.55
Depreciation / Amortisation	-350,398.31	-418,018.95
Other operational expenses	-2,959,048.42	-2,607,745.20
EBIT (earnings before interest and tax)	10,653,925.13	6,116,206.80
Interest income	23,758.52	1,764.50
Income from investments	560.23	
Financial investment depreciations	-19,910.40	
Interest expense	-651,312.69	-314,976.78
Financial Result	-646,904.34	-313,212.28
EBT (earnings before tax)	10,007,020.79	5,802,994.52
Income tax	-270,430.82	-769,468.82
Other tax	-1,549.00	-849.00
Net profit for the reporting period	9,735,040.97	5,032,676.70
thereof, attributed to:		
Shareholders of MPH	6,967,026.22	5,032,676.70
Non-controlling shareholders	2,768,014.75	
	9,735,040.97	

* Accounting under IFRS

Group cash flow statement

for the period from 1 January to 30 June*

	2012 EUR	2011 EUR
Cash flow from operating activities	-5,844,444.31	1,292,104.00
Cash flow from investment activities	-525,065.06	-444,575.03
Cash flow from financing activities	5,233,424.13	-664,295.47
Change in cash and cash equivalents due to changes in companies consolidated	7,677,724.61	
Cash flow	6,541,639.37	183,233.50
Liquid Funds		
30 June 2012 / 2011	8,998,460.08	939,855.12
31 December 2011 / 2010	2,456,820.71	756,621.62
	6,541,639.37	183,233.50

* Accounting IFRS

Group equity change account

as at 30 June 2012*

	Share capital EUR	Acquired own shares EUR	Capital reserve EUR	Capital reserve for own shares EUR	Other revenue reserves EUR	Retained earnings EUR	Sub-total EUR	Equity of shareholders of		Non-controlling shareholders EUR	Total equity EUR
								MPH EUR	shareholders EUR		
1. As at 31 December 2011/ 1 January 2012	38,050,000.00	0.00	0.00	0.00	0.00	11,239,247.90	49,289,247.90	49,289,247.90	0.00	0.00	49,289,247.90
2. Increase in the share capital	3,117,155.00	0.00	4,332,845.00	0.00	0.00	0.00	7,450,000.00	7,450,000.00	0.00	0.00	7,450,000.00
3. Net profit for the period	0.00	0.00	0.00	0.00	0.00	6,967,026.22	6,967,026.22	6,967,026.22	2,768,014.75	0.00	9,735,040.97
4. Reclassifications / Initi- al consolidation	0.00	-4,316,344.00	0.00	-6,151,863.84	-3,354.94	0.00	-10,471,562.78	-10,471,562.78	12,482,179.03	0.00	2,010,616.25
5. As at 30 Juni 2012	41,167,155.00	-4,316,344.00	4,332,845.00	-6,151,863.84	-3,354.94	18,206,274.12	53,234,711.34	53,234,711.34	15,250,193.78	15,250,193.78	68,484,905.12

* Accounting under IFRS

Group assets development

as at 30 June 2012*

	As of 31.12.2011		Addition due to initial con-solidation		Addition/ Recl.		Disposal/ Recl.		Acquisition cost		As of 31.12.2011		Addition due to initial con-solidation		Disposal		Cumulative depreciation / amortisation		As of 30.06.2012		Book values		
	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR	EUR
I. Intangible assets																							
1. Intangible assets																							
2. Company value	1,988,458.67	7,933,054.12	290,588.26	0.00	0.00	10,212,101.05	0.00	0.00	0.00	0.00	3,948,596.99	302,659.23	0.00	4,936,697.89	0.00	0.00	0.00	4,936,697.89	5,275,403.16	40,168,339.00	37,321,621.72	1,303,017.00	
	37,321,621.72	2,000.00	2,846,717.28	0.00	0.00	40,170,339.00	0.00	0.00	0.00	0.00	2,000.00	0.00	0.00	2,000.00	0.00	0.00	0.00	2,000.00	40,168,339.00	45,443,742.16	38,624,638.72	38,624,638.72	
	39,310,080.39	7,935,054.12	3,137,305.54	0.00	0.00	50,382,440.05	0.00	0.00	0.00	0.00	3,950,596.99	302,659.23	0.00	4,938,697.89	0.00	0.00	0.00	4,938,697.89	45,443,742.16	38,624,638.72	38,624,638.72	38,624,638.72	
II. Fixed assets																							
1. Lessee installed equip-ments																							
2. Other fixed assets	8,000.00	0.00	0.00	0.00	0.00	8,000.00	0.00	0.00	0.00	0.00	0.00	400.00	0.00	2,667.00	0.00	0.00	0.00	2,667.00	5,333.00	5,333.00	5,733.00	5,733.00	
	441,953.32	942,098.39	243,700.00	0.00	0.00	1,627,751.71	0.00	0.00	0.00	0.00	170,676.54	47,339.08	0.00	396,162.94	0.00	0.00	0.00	396,162.94	1,231,588.77	1,231,588.77	263,806.00	263,806.00	
	449,953.32	942,098.39	243,700.00	0.00	0.00	1,635,751.71	0.00	0.00	0.00	0.00	170,676.54	47,739.08	0.00	398,829.94	0.00	0.00	0.00	398,829.94	1,236,921.77	1,236,921.77	269,539.00	269,539.00	
III. Prepayments on intangible and tangible assets																							
IV. Associated com-panies																							
V. Financial assets	0.00	336,194.09	-24,477.51	0.00	0.00	311,716.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	311,716.58	2,450,000.00	240,452.90	3,548,985.06	
	0.00	0.00	2,450,000.00	0.00	0.00	2,450,000.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,450,000.00	49,682,833.41	42,443,162.78	42,443,162.78	
	3,420,684.65	1,574,434.48	15,254.31	-3,420,684.65	15,254.31	1,589,688.79	-3,420,684.65	-3,420,684.65	-128,300.41	1,351,357.49	19,910.40	1,349,235.89	-106,268.41	1,349,235.89	-106,268.41	-106,268.41	-106,268.41	1,349,235.89	240,452.90	49,682,833.41	42,443,162.78	42,443,162.78	
TOTAL	43,180,718.36	10,787,781.08	5,821,782.34	-3,420,684.65	5,821,782.34	56,369,597.13	-3,420,684.65	-3,420,684.65	737,555.58	5,472,631.02	370,308.71	6,686,763.72	-106,268.41	6,686,763.72	-106,268.41	-106,268.41	-106,268.41	6,686,763.72	49,682,833.41	42,443,162.78	42,443,162.78	42,443,162.78	

* Accounting under IFRS

Additional information

Information about members of the company bodies.....	20
Number of employees.....	20
The share	21
Glossary.....	22
Imprint	23

Information about members of the company bodies

Board of Directors

Name	Position / authority to act	Profession
Patrick Brenske (from 23.01.2009)	Board member Authorized to act solely	Master of Banking & Finance
Dr. Christian Pahl (from 17.05.2010)	Board member Together with another board member	Master of Business Administration

Supervisory Board

Name	Position / authority to act	Profession
Andrea Grosse	Chairwoman	Lawyer
Prof. Dr. Dr. Sabine Meck	Deputy Chairwoman	University Professor and Science Journalist
Dr. Marion Braun	Member	Doctor

Number of employees

On June 30, 2012, the MPH-Group employed 121 staff members. Due to existing part-time contracts, this number corresponds to 97 full-time employees.

The share

Classes of Shares	Ordinary shares and preference shares
Number of ordinary shares	22,142,155
Number of preference shares	19,025,000
Market listed shares	Preference shares
WKN / ISIN	A0NF69 / DE000A0NF697
Stock symbol	93MV
Trading floor	Xetra, Frankfurt
Market segment	Entry Standard (Open Market)
Designated Sponsor, Listing Partner	Close Brothers Seydler Bank AG
Market Capitalisation	Preference shares 48.13 Mio. (as at 29.06.2012)
Coverage	Hauck & Aufhäuser, GBC AG, Silvia Quandt & Cie.

Glossary

Cash Flow

An economic indicator informing on the liquidity of a company. It represents the increase of liquid funds during a period.

DAX

DAX is the most important German share price index. It reflects the development of the 30 largest companies in Germany with the highest turnover.

Dividend

This is the part of distributed profit of a stock corporation attributed to an individual share.

EBIT

It means earnings before interest and taxes and is an indicator of the operating profit of a company in a given period.

EBITDA

It means earnings before interest, taxes, depreciation and amortization and corresponds to the EBIT plus depreciation and amortization of tangible and intangible assets.

Earnings per share

The earnings per share result from dividing the group result by the weighted average of the number of shares. The calculation is made according to IAS 33.

Patent

In application to drugs: for a newly developed pharmaceutical agent, an industrial property right is granted. In the EU, this market exclusivity limited in time can last up to 20 years.

Patent-free agents

Patent-free agents are also called generic drugs. A generic drug is a drug that is a copy of another drug already on the market under a brand name with the same active agent. Generic drugs are therapeutic equivalents to the original preparation

Patent-protected agents

Branded drugs that on the one hand are marketed by the patent owner and on the other hand are purchased for a lower price within the EU member states as EU imported drugs on the basis of the legal base of the import.

Oncology

Oncology is the science dealing with cancer.

Approval

An official authorization which is required to be able to offer, distribute or provide an industrially produced, ready-to-use drug.

Imprint

MPH Mittelständische Pharma Holding AG
Hubertusallee 73
14193 Berlin

Phone: +49 (0) 30 897 308 660

Fax: +49 (0) 30 897 308 670

E-Mail: info@mph-ag.de

Web: www.mph-ag.de

Supervisory Board:

Chairwoman of the supervisory board:

Andrea Grosse

Deputy chairwoman of the supervisory board:

Prof. Dr. Dr. Sabine Meck

Member of the supervisory board:

Dr. Marion Braun

Management board:

Patrick Brenske

Dr. Christian Pahl

Register court: district court Charlottenburg

Register number: HRB 116425 B

Conception, design and realization:

MPH Mittelständische Pharma Holding AG

Investor Relations

Photos:

MPH Mittelständische Pharma Holding AG

